PubMed Health⌕ Search

Biomedical subjects

M Carson

Publications and source records attributed to M Carson.

At least 73 records · Page 4Linked to original sources
PubMed1981

In-vitro activity of erythromycin against anaerobic microorganisms.

Minimum inhibitory concentrations of erythromycin were determined, in the absence of CO2, for 256 strains of anaerobic microorganisms recently isolated from clinical practice. Of 126 strains of Bacteroides fragilis, 93% were inhibited by 6 mg/L, or less, of erythromycin. Of the remaining 130 isolates, 92% were inhibited by 6 mg/L, or less, of erythromycin. These findings suggest that the majority of anaerobic microorganisms would be inhibited by the serum levels achieved by administering 1 g of erythromycin intravenously, every six hours.

Bacteria↗
PubMed1981

Comparison of the activity of cefoperazone, cefuroxime and cefoxitin against Gram-negative bacilli and synergy studies with cefoperazone and ticarcillin.

83% of at least 11 different species of Gram-negative aerobic bacilli, comprising 270 clinical isolates, were inhibited by 3.1 microgram cefoperazone per ml. 55% and 48% were inhibited by 3.1 micrograms/ml of cefuroxime and cefoxitin, respectively. In addition, cefoperazone inhibited 83 of 96 Pseudomonas aeruginosa isolates at a concentration of 6.2 microgram/ml. Cefoperazone/ticarcillin combinations were shown to be synergistic for 47/96 (49%) of Pseudomonas aeruginosa isolates studied, when lowering of the minimum bactericidal concentrations of the 2 drugs was the criterion for enhancement of activity. Cefoperazone/ticarcillin combinations were also shown to be synergistic against 15/30 Serratia marcescens isolates. We discuss the possible advantages of synergistic combinations of drugs of relatively low toxicity, for the management of complicated infections.

Anti-Bacterial Agents↗
PubMed1981

The role of the laboratory in the planned use of cefoperazone for the treatment of difficult Pseudomonas infections.

Four cases are discussed illustrating the role of the laboratory in the treatment of difficult pseudomonas infections. Pseudomonas vertebral osteomyelitis, in a 76-year-old man with impaired renal function, was successfully treated with cefoperazone given for 7 weeks. A 73-year-old woman, who had recurrent pseudomonas septicaemia due to infected cardiac pacing wires (that could not be removed), was managed with long term daily intramuscular cefoperazone, and a 31-year-old woman with pseudomonas aortitis was treated with long term intravenous cefoperazone. A 47-year-old man, who developed a pseudomonas infection superimposed on chronic osteomyelitis of the femur prior to a free vascularised graft operation, was treated with cefoperazone and ticarcillin.

Adult↗
PubMed1980

Pyrido[2,1-b]quinazolinecarboxylic acids as orally active antiallergy agents.

A series of 8-substituted pyrido[2,1-]quinazoline-2-carboxylic acids was prepared by the nickel carbonyl mediated carboxylation of the corresponding bromides. The activities of these compounds in the rat PCA test are comparable to those of the corresponding 2-substituted pyrido[2,1-b]quinazoline-8-carboxylic acids.

Administration, Oral↗
PubMed1976

A new semisynthetic macrolide antibiotic 3-O-oleandrosyl-5-O-desosaminylerythronolide A oxime.

A new antibiotic, 3-O-oleandrosyl-5-O-desosaminylerythronolide A oxime (3) was produced from erythronolide A oxime (1) by the oleandomycin-producing culture, Streptomyces antibioticus ATCC 11891. The structure of 3 was determined by degradative studies and confirmed by X-ray analysis. Compound 3 was found to be less active, but more stable to acid, then erythromycin A oxime.

Anti-Bacterial Agents↗
PubMed1975

Aromatic esters of 5-O-desosaminylerythronolide A oxime.

Several substituted aromatic esters of the C-3 hydroxyl of 5-O-desosaminylerythronolide A oxime were prepared. Ribosomal binding studies showed that meta substituents on the aromatic ring gave the most active analogs. The esters described were all inactive in vivo at the maximum level tested.

Bacillus subtilis↗
PubMed1974

Phenotype recognition of pyocyanine mutants in pseudomonas aeruginosa.

Certain classes of pyocyanine mutants in Pseudomonas aeruginosa escape detection when screened in the presence of wild-type or other mutant cells. A technique is described for recognizing mutant phenotypes after cells are in individual agar wells. The procedure eliminates cross-feeding phenomena as well as the masking of mutant phenotypes by diffusing pyocyanine produced by nearby clones.

Agar↗